SCHEMBL3726388

SCHEMBL3726388

CCC(C(=O)O)(c1ccccc1)C(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.52
CYP2D6 P10635 2/20 0.52
CYP2C19 P33261 2/20 0.46
HIF1A Q16665 1/20 0.46
KIF11 P52732 3/20 0.41
GRIN2D O15399 2/20 0.41
GRIN1 Q05586 2/20 0.41
GRIN2A Q12879 2/20 0.41
GRIN2B Q13224 2/20 0.41
GRIN2C Q14957 2/20 0.41
OPRM1 P35372 2/20 0.41
CACNA1F O60840 1/20 0.41
ABCB1 P08183 1/20 0.41
CYP2B6 P20813 1/20 0.41
DRD4 P21917 1/20 0.41
DRD3 P35462 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
CACNA1D Q01668 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27467076 0.85 CYP1A2 (0.44) CYP1A2CYP2D6CYP2C19HIF1AKIF11
SCHEMBL4055704 0.85 CYP2D6 (0.49) CYP1A2CYP2D6CYP2C19HIF1AKIF11
SCHEMBL6758874 0.85 CYP2D6 (0.52) CYP1A2CYP2D6CYP2C19HIF1AKIF11
SCHEMBL11786526 0.83 CYP1A2 (0.50) CYP1A2CYP2D6CYP2C19HIF1AKIF11
SCHEMBL10692707 0.83 CYP2C19 (0.58) CYP1A2CYP2D6CYP2C19HIF1AKIF11
SCHEMBL4963270 0.82 KCNN4 (0.53) CYP1A2CYP2D6CYP2C19HIF1AOPRM1
SCHEMBL28779828 0.81 KIF11 (0.43) CYP1A2CYP2D6CYP2C19HIF1AKIF11
SCHEMBL28478140 0.81 CYP2D6 (0.45) CYP1A2CYP2D6CYP2C19HIF1AKIF11
SCHEMBL29010715 0.79 ALDH1A1 (0.42) CYP1A2CYP2D6KIF11CNR2
SCHEMBL28651797 0.79 CYP2D6 (0.39) CYP1A2CYP2D6KIF11GRIN2DGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339184-B2 Antibacterial compounds, compositions thereof, and methods using same THE ROCKEFELLER UNIVERSITY (US) 2022-05-24 US disclosed
WO-2021242849-A1 ANTIBACTERIAL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS USING SAME THE ROCKEFELLER UNIVERSITY (US) 2021-12-02 WO disclosed
US-20210024562-A1 ANTIBACTERIAL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS USING SAME THE ROCKEFELLER UNIVERSITY 2021-01-28 US disclosed
CN-107532160-A The manufacture method and microorganism formulation of microorganism formulation 住友化学株式会社 2018-01-02 CN disclosed
US-7812038-B2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS, INC. (US) 2010-10-12 US disclosed
US-20060276476-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors BIEDIGER RONALD J 2006-12-07 US disclosed
US-6972296-B2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC. (US) 2005-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276476-A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors VCAM1, ICAM1, ITGA1 CYP1A2 2894/4885CYP2D6 3905/4885CYP2C19 2494/4885
US-11339184-B2 Antibacterial compounds, compositions thereof, and methods using same CLPP, MPO, SPOUT1 CYP1A2 4330/4885CYP2D6 3928/4885CYP2C19 4449/4885
US-20210024562-A1 ANTIBACTERIAL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS USING SAME CLPP, MPO, SPOUT1 CYP1A2 4330/4885CYP2D6 3928/4885CYP2C19 4449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.